Adding A Personalized MRNA VACCINE TO STANDARD TREATMENT COULD OFFER NEW HOPE FOR PANCREATIC CANCER PATIES, SMALL YET PROMISING STUDY FROM MEMORIAL SLOAN KETTERING CANCER CENTER.
The Study Followed 16 Patients, Including Barbara Brigham, Who Joined the trial after Routine Scan Discoved Her Early-Stage Pancreatic Cancer.
ALONGSIDE SURGERY AND CHEMOTHERAPY, PATIES RECEIVED A CUSTOMIZED MRNA VACCINE, Designed Using Their Own Tumors. UNLIKE VACCINES THAT AIM TO PREVENT DISEASE IN THE FIRST PLACE, THIS ONE AIMS TO HELP A PATENT’S OWN IMMEMEMM SYSTEM FIGHT THEIR CANCER.
BRIGHAM, 74-youar-ord Semi -retired Librarian from long island, didn’t hesitate to try it.
“The Prognosis Was Not Good When I Was Diagnosed,” She Said in A CBS News Report. “You Know You’re Going To Have A Limited Amount of Time.
The MRNA VACCINE WORKS BY TARGETING GENETIC MUTATIONS FOUND IN PANCREATIC CANCER, Alerting the Imamune System To Recognize and Attack The Tumor.
DURING SURGEY, Doctors Removed Each Patient’s Tumor and Sent It to the German Biotechnology Company Biontech.
Patients then Received Their Personalized Vaccine Along with Immunotherapy and Chemotherapy.
BECAUSE “THE IMMEMCHE SYSTEM IS HARDWIRED NOT TO COLLECTIZ OUT OWN BODY,” IT’S TYPICALLY CHALLENGING TO TEACH IT TO CANCER, SAID SURGICAL ONCOLOGIST Dr. Vinod Balachandran, Who Specializes in Pancreatic Cancer Treatment. “
Of the 16 Patients Who Participated in the Study, Eight Had a Strong Imamune Response, and Six of Those Eight Remained Cancer Nature.
In Contrast, Seven of the Eight Patients Who Didn’t Respond Saw Their Cancer Return. The Difference Seemed to Depend on When the Patient’s Spleen Was Removed During Surgery, The Spleen Plays A Critical Rolle in Imamune Function.
“It’s Still Hard to Attribute Causality to the Vaccine Alone,” Balachandran Caucioned, Emphasizing the Trial’s Small Size.
Dr. Suneel Kamath, the gastrointestinal Oncologist at Cleveland Clinic Who Review the Findings, Pointed Out That the Survival Rate of the Patients In the Try Survival Rate of Those with Early-Stage Pancreatic Cancer Treated with Surgery and Chemo.
“This a nice kind of proof-of-conception study to show that we can make a vaccine for this disease, and it really does currently cream an immune response, and an immares response that lasts,” kamath told CBS News. “That’s a Very Nice Backbone to Build off of.”
A Larger, Randomized Trial is Now Underway, Focusing on Early-Stage Pancreatic Cancer Patients Whitee Spleens Are intact.
“The Beauty of Mrna Vaccines, the We Saw With Covid Development, is the look fast to make. It’s easy to Generat. Said.
“It’s really exciting, Because when we talk about Curing cancer, It’s not really a single monolithic disease,” he added. “There are probably Husndreds of different targets for Every Cancer Type. And so the ability to make vaccines againt a lot of tose different targets very quickly is really powerful.”
Researchers are also exploiting mrna vaccines for melanoma and cancers of the kidney and lung, whiche Theorize May Respond Better BECAUSE OF THEIR ABILITY TO MUTATE MORE.
For Brigham, The Trial Gave Her Exactly What She Hoped For – More Time.
In the Past Few Months, She Welcomed Her Eighth Grandbaby and Celebrated Her Brother’s 60th Wedding Anniversary.
“The Trial Was Such a Wondrous Thing,” She Said. “It has just given me such a renewal in my life. Sometimes It’s a Little Difficult, but it’s worth it, Absolutely Worth it.”
More information:
Zachary Sethna et al, RNA Neoantigen Vaccines Prime Long Lived CD8+ T Cells in Pancreatic Cancer, Nature (2025). DOI: 10.1038/S41586-024-08508-4
Copyright © 2025 Healthday. All Rights Reserved.
Citation: VACCINE SHOWS PROMISISE FOR PANCREATIC CANCER, STUDY Finds (2025, February 21) Retrieved 22 February 2025 from
This document is Subject to Copyright. Apart from Any Fair Dealing for the Purpose of Private Study or Research at Part May Be Reproduced Without The Written Permission. The Content is Provided for Information Purposes Only.
